Top accelerator startups

14,448 startups · 29 programs

Abalone Bio

Active · We create activating antibodies to treat diseases others can’t.

10signal of 100 · rising 2
  • team of 14Team size · YC's directory+6.1
  • went through YCProgram · this site+4

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from W20 in AI

All of W20

About Abalone Bio

Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs) + Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech. + Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. + Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.

YC batch
W20 · Winter 2020
Status, per YC
Active
Category
AI
Team size
14
Location
San Francisco, CA, USA
Checked
6h ago

YC tags: Machine Learning, Synthetic Biology, Therapeutics, Drug discovery

Abalone Bio in W20: 229 companies, 29% AI

Abalone Bio: questions

Which YC batch was Abalone Bio in?

Abalone Bio was in Y Combinator's Winter 2020 batch (W20).

Is Abalone Bio still active?

Y Combinator lists Abalone Bio as active.

Where is Abalone Bio based?

Abalone Bio lists San Francisco, CA, USA as its location on YC's directory.